We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02792725
Title Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Pacific Cancer Care Monterey California 93940 United States Details
UCLA Medical Center Santa Monica California 90404 United States Details
Orlando Health, Inc Orlando Florida 32806 United States Details
Rush University Medical Center Chicago Illinois 60612 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
University of Minnesota Medical Center, Fairview Lakes Wyoming Minnesota 55092 United States Details
Saint Luke's Cancer Institute Kansas City Missouri 64111 United States Details
Memorial Sloan Kettering Cancer Center Commack New York 11725 United States Details
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas 75246 United States Details
West Virginia University Hospital Morgantown West Virginia 26506 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field